Prostate-specific membrane antigen–targeted PET/CT using [68Ga]Ga-PSMA-11, originally developed for prostate cancer, has occasionally demonstrated uptake in osteosarcomas, Ewing sarcomas, and other high-grade soft-tissue sarcomas, suggesting potential relevance for tumor characterization and theranostic applications [112]. This evidence concerns the gene FOLH1 and prostate carcinoma.